Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Watson Pharmaceuticals Inc Receives FDA Approval


Thursday, 3 Jan 2013 09:00am EST 

Watson Pharmaceuticals Inc announced that its subsidiary Watson Laboratories, Inc. Florida has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for tranexamic acid tablets, the generic equivalent to Ferring Pharmaceuticals' Lysteda. Watson intends to begin shipping the product immediately. Lysteda is indicated for the treatment of cyclic heavy menstrual bleeding. Ferring B.V. has filed lawsuits against Watson, alleging that Watson's ANDA product infringes U.S. Patent Nos. 7,947,739, 8,022,106, and 8,273,795. The litigations remain pending. 

Company Quote

220.84
3.19 +1.47%
14 Jul 2014